Join D2R and the Victor Phillip Dahdaleh Institute of Genomic Medicine for this hybrid seminar on Tuesday November 26 at 9am (EST) titled “The Wellcome Leap R3 Program: RNA Readiness and Response”.

Guest speaker Duccio Medini, a scientist and pharmaceutical executive, currently serving as R3 Program Director at Wellcome Leap, will talk about the R3 program which aims to increase access to biologics development in non-emergency times and to create economically sustainable, equitably distributed surge capacity in pandemic emergency (20B vaccine doses/month).

Abstract

The Wellcome Leap R3 program, jointly funded with CEPI, aims to increase access to biologics development in non-emergency times and to create economically sustainable, equitably distributed surge capacity in pandemic emergency (20B vaccine doses/month). The R3: RNA Readiness and Response program, took a page from the semiconductor industry transformation in the 1980s, which developed multi-product foundries with standardized processes and design tools that exploded global innovation.

This session will cover R3 advances in (i) manufacturing processes, with potential for 10mg to 1kg of RNA-based product, or up to 100 products, per day, in a 35 m2 footprint; (ii) vaccines and therapeutic products that target >30X dose-reduction and >100X cost-reduction compared to state-of-the-art; (iii) in-silico design tools that enable >5X dose-reduction and manufacturability verification with >90% accuracy, for a democratized access to the RNA Ecosystem.

https://www.mcgill.ca/dna-to-rna/channels/event/seminar-wellcome-leap-r3-program-rna-readiness-and-response-360576